Evidence map›Paper›PMID 29996912›Full record

ReviewStem cell research & therapy2018

Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research.

Lara Lopes, Ocean Setia, Afsha Aurshina, Shirley Liu, Haidi Hu, Toshihiko Isaji, Haiyang Liu, Tun Wang, Shun Ono, Xiangjiang Guo and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Translational development of ABCB5Stem cell research & therapy · 2022
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Review
  14. Review
  15. Advances in Stem Cell Therapy for Diabetic Foot Ulcers.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Lara LopesVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Ocean SetiaVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Afsha AurshinaVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Shirley LiuVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Haidi HuVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Toshihiko IsajiVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Haiyang LiuVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Tun WangVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Shun OnoVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Xiangjiang GuoVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Bogdan YatsulaVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA.
Jianming GuoDepartment of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Yongquan GuDepartment of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Tulio NavarroFaculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Alan DardikVascular Biology and Therapeutics Program and Department of Surgery , Yale School of Medicine, Yale University, New Haven, CT, USA. alan.dardik@yale.edu.
Yale University · USCapital Medical University · CNUniversidade Federal de Minas Gerais · BRVA Connecticut Healthcare System · US

Funding

Research Training in AnesthesiaT32GM086287 · NIGMS · YALE UNIVERSITY · PI ROBERT SCHONBERGER · 2009 to 2026
$3.7M
Enhancing venous adaptation to the arterial environmentR01HL128406 · NHLBI · YALE UNIVERSITY · PI DARDIK, ALAN · 2016 to 2019
$1.9M
NHLBI NIH HHS R01 HL128406NIGMS NIH HHS T32 GM086287
6 · The paper itself

Abstract

backgroundDiabetic foot ulcer (DFU) is a severe complication of diabetes, preceding most diabetes-related amputations. DFUs require over US$9 billion for yearly treatment and are now a global public health issue. DFU occurs in the setting of ischemia, infection, neuropathy, and metabolic disorders that result in poor wound healing and poor treatment options. Recently, stem cell therapy has emerged as a new interventional strategy to treat DFU and appears to be safe and effective in both preclinical and clinical trials. However, variability in the stem cell type and origin, route and protocol for administration, and concomitant use of angioplasty confound easy interpretation and generalization of the results.

methodsThe PubMed, Google Scholar, and EMBASE databases were searched and 89 preclinical and clinical studies were selected for analysis.

resultsThere was divergence between preclinical and clinical studies regarding stem cell type, origin, and delivery techniques. There was heterogeneous preclinical and clinical study design and few randomized clinical trials. Granulocyte-colony stimulating factor was employed in some studies but with differing protocols. Concomitant performance of angioplasty with stem cell therapy showed increased efficiency compared to either therapy alone.

conclusionsStem cell therapy is an effective treatment for diabetic foot ulcers and is currently used as an alternative to amputation for some patients without other options for revascularization. Concordance between preclinical and clinical studies may help design future randomized clinical trials.

Indexed as

Amputation, SurgicalCell- and Tissue-Based TherapyDiabetes ComplicationsDiabetic FootHumansWound HealingAmputationCell therapyCritical limb ischemiaDiabetic foot ulcerDiabetic woundStem cell therapyWound healing

Identifiers

PMID29996912
PMCPMC6042254
OpenAlexW2814793787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.